Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

527
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
527
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

2.7K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Localization of inhibin alpha-subunit immunoreactivity in the rat adrenal cortex.

Journal of neuroendocrinology·2009
Same author

A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.

British journal of cancer·2006
Same author

Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile.

Journal of musculoskeletal & neuronal interactions·2005
Same author

Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium.

The Journal of clinical endocrinology and metabolism·1999
Same author

Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women.

The Journal of clinical endocrinology and metabolism·1999
Same author

Modulating mechanisms of neuroendocrine cell activity: the LHRH pulse generator.

Cellular and molecular neurobiology·1998
Same journal

Changes in matrix metalloproteinase 2 activities in amniochorions during premature rupture of membranes.

Journal of the Society for Gynecologic Investigation·2006
Same journal

An animal model of intrauterine growth retardation induced by synthetic thromboxane a(2).

Journal of the Society for Gynecologic Investigation·2006
Same journal

Leptin suppresses human chorionic gonadotropin-induced cyclooxygenase-2 expression and prostaglandin production in cultured human granulose luteal cells.

Journal of the Society for Gynecologic Investigation·2006
Same journal

Chronic tumor necrosis factor-alpha infusion in gravid C57BL6/J mice accelerates adipose tissue development in female offspring.

Journal of the Society for Gynecologic Investigation·2006
Same journal

Genetic associations in preterm birth: a primer of marker selection, study design, and data analysis.

Journal of the Society for Gynecologic Investigation·2006
Same journal

Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids.

Journal of the Society for Gynecologic Investigation·2006
See all related articles

Related Experiment Video

Updated: Feb 18, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K

New progestins and potential actions.

A Negro-Vilar1

  • 1Ligand Pharmaceuticals Inc., San Diego, California 92121, USA.

Journal of the Society for Gynecologic Investigation
|March 25, 2000
PubMed
Summary
This summary is machine-generated.

Newer progestins are being developed using a molecular approach targeting the human progesterone receptor (hPR). These compounds aim for tissue selectivity and minimal side effects, offering improved therapeutic potential.

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

20.1K

Related Experiment Videos

Last Updated: Feb 18, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

20.1K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Molecular Biology

Background:

  • Development of novel progestins is crucial for targeted therapies.
  • Existing progestins may have undesirable side effects or lack tissue selectivity.

Purpose of the Study:

  • To describe the development of newer, nonsteroidal, orally active, tissue-selective progestins.
  • To outline the molecular approach utilizing the human progesterone receptor (hPR) as the target.
  • To define the desirable characteristics of next-generation progestin compounds.

Main Methods:

  • Molecular approach for compound selection targeting the human progesterone receptor (hPR).
  • Co-transfection and binding assays to assess receptor selectivity and cross-reactivity.
  • Analysis of transcriptional products to profile new progestin compounds.

Main Results:

  • New progestins are being developed with a focus on hPR as the molecular target.
  • Assays are employed to ensure selectivity and minimize off-target effects.
  • Compounds are profiled for specific desirable characteristics.

Conclusions:

  • Newer progestins are under development with a molecular-driven, tissue-selective approach.
  • These compounds aim to possess beneficial properties such as suppressing endometrial stimulation and maintaining pregnancy.
  • The goal is to achieve efficacy with minimal adverse physiological effects.